Navigation Links
Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinova's Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements
Date:10/23/2007

COLUMBIA, Md., Oct. 23 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) today announced that a three-judge panel of a district court in Dusseldorf, Germany, has orally announced a judgment in favor of Martek in the company's patent infringement suit against (i) Lonza Ltd., (ii) Celanese Ventures GmbH and (iii) Nutrinova Nutrition Specialties & Food Ingredients GmbH. In a separate suit against Lichtwer Pharma GmbH, one of Nutrinova's customers, a similar judgment was announced. The first suit involves Lonza's German sale and use of a fatty acid product currently marketed under the brand name Lonza DHA for use in functional foods and dietary supplements. The second suit involves Lichtwer's German sale and use of a DHA-containing oil in a supplement marketed under the brand name AMEU(R) Alge. The Martek patent that has been infringed is European Patent No. 0 515 460 relating to microbial oils containing at least 35% DHA (docosahexaenoic acid).

The court is expected to deliver its written judgments within thirty days. The decisions may be appealed by Lonza and Lichtwer to the higher regional court in Dusseldorf. The patent infringed by Lonza and Lichtwer has been the subject of opposition proceedings at the European Patent Office since 1999 and a final resolution of those proceedings is expected at some time in the second half of 2008. In October 2006, a jury in a U.S. federal district court in Delaware determined that Lonza's DHA activities in the functional food and dietary supplement areas infringed three U.S. Martek patents.

"We are very pleased that the court found that the actions of Lonza and Lichtwer infringe this European DHA patent of Martek. The decision further demonstrates both the company's resolve to vigorously defend its intellectual property portfolio and the strength of Martek's patent portfolio in the marketplace," said Steve Dubin, CEO of Martek.

About Martek Biosciences

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com.

Forward-Looking Statements

Sections of this release contain forward-looking statements, including, without limitation, statements concerning the course and outcome of current and future legal proceedings and the strength of Martek's patent portfolio. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. For instance, Martek cannot predict with certainty any events associated with the litigation and appeal process, the future actions of Lonza or Lichtwer, the future actions of Martek's customers or prospective customers or the competitive and financial impact of any final court decision on the value of Martek's intellectual property. These statements should be understood in light of the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's Forms 8-K, 10-Q and 10-K.

CONTACT

Cassie France-Kelly

Public Relations

(443) 542-2116

cfrancekelly@martek.com

Kyle Stults

Investor Relations

(410) 740-0081

investors@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. German hospital established in Kashmir for earthquake relief
2. First Crossover Kidney Transplantation In Germany
3. Birds Flu Scare Reaches Germany
4. Karla: healthy beer as claimed by German manufacturers
5. Germany could start indoor poultry to avoid bird flu infection
6. MIOT Hospital Signs Agreement With German Healthcare Facility
7. German Nurse Makes A Confession
8. Indian Doctor Establishes His Name In Germany
9. Poultry Ordered Indoors Following Bird Flu Suspicion In Germany
10. New Bird Flu Cases In Germany Prompts Massive Culling Of Poultry
11. A warning and wake up call: German cat infected with deadly bird flu strain.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... the life cycle of pharmaceutical products, garnering increased attention from all stakeholders in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut water beverages ... GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature ... event. The invitation-only gifting suite, held this year at the W Hollywood Hotel, has ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance firm ... that will raise funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd ... school is in a low-income area and has more than 60 2nd and 3rd ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016  Sequent Medical, Inc. gab heute bekannt, ... eine Studie zur Sicherheit und Wirksamkeit des WEB™-Systems ... Behandlung von rupturierten intrakraniellen Aneurysmen begonnen hat. Prof. ... an der Universitätsklinik Bicètre in Paris ... den ersten Patienten aufgenommen. Im Rahmen ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company (NYSE: ... decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not ... UK, France , Italy ... dilute the product only with dextrose solution.  ... the UK Court of Appeal held that Lilly,s patent would ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
Breaking Medicine Technology: